Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations
- Western blot [2]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 500-P05-1MG - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- PF4 Polyclonal Antibody, PeproTech®
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- AA Sequence of recombinant protein: EAEEDGDLQC LCVKTTSQVR PRHITSLEVI KAGPHCPTAQ LIATLKNGRK ICLDLQAPLY KKIIKKLLES.
- Concentration
- 0.1-1.0 mg/mL
Submitted references Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation.
Platelet factor 4 mediates vascular smooth muscle cell injury responses.
Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor.
Serglycin proteoglycan deletion induces defects in platelet aggregation and thrombus formation in mice.
Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.
Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin.
Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells.
Johnston I, Sarkar A, Hayes V, Koma GT, Arepally GM, Chen J, Chung DW, López JA, Cines DB, Rauova L, Poncz M
Blood 2020 Apr 9;135(15):1270-1280
Blood 2020 Apr 9;135(15):1270-1280
Platelet factor 4 mediates vascular smooth muscle cell injury responses.
Shi G, Field DJ, Long X, Mickelsen D, Ko KA, Ture S, Korshunov VA, Miano JM, Morrell CN
Blood 2013 May 23;121(21):4417-27
Blood 2013 May 23;121(21):4417-27
Identification of the platelet-derived chemokine CXCL4/PF-4 as a broad-spectrum HIV-1 inhibitor.
Auerbach DJ, Lin Y, Miao H, Cimbro R, Difiore MJ, Gianolini ME, Furci L, Biswas P, Fauci AS, Lusso P
Proceedings of the National Academy of Sciences of the United States of America 2012 Jun 12;109(24):9569-74
Proceedings of the National Academy of Sciences of the United States of America 2012 Jun 12;109(24):9569-74
Serglycin proteoglycan deletion induces defects in platelet aggregation and thrombus formation in mice.
Woulfe DS, Lilliendahl JK, August S, Rauova L, Kowalska MA, Abrink M, Pejler G, White JG, Schick BP
Blood 2008 Apr 1;111(7):3458-67
Blood 2008 Apr 1;111(7):3458-67
Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications.
Lambert MP, Rauova L, Bailey M, Sola-Visner MC, Kowalska MA, Poncz M
Blood 2007 Aug 15;110(4):1153-60
Blood 2007 Aug 15;110(4):1153-60
Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications.
Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M
Blood 2006 Mar 15;107(6):2346-53
Blood 2006 Mar 15;107(6):2346-53
Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia.
Rauova L, Poncz M, McKenzie SE, Reilly MP, Arepally G, Weisel JW, Nagaswami C, Cines DB, Sachais BS
Blood 2005 Jan 1;105(1):131-8
Blood 2005 Jan 1;105(1):131-8
Transgenic mice studies demonstrate a role for platelet factor 4 in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin.
Eslin DE, Zhang C, Samuels KJ, Rauova L, Zhai L, Niewiarowski S, Cines DB, Poncz M, Kowalska MA
Blood 2004 Nov 15;104(10):3173-80
Blood 2004 Nov 15;104(10):3173-80
Platelet factor 4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells.
Nassar T, Sachais BS, Akkawi S, Kowalska MA, Bdeir K, Leitersdorf E, Hiss E, Ziporen L, Aviram M, Cines D, Poncz M, Higazi AA
The Journal of biological chemistry 2003 Feb 21;278(8):6187-93
The Journal of biological chemistry 2003 Feb 21;278(8):6187-93
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot: To detect Human PF-4 (CXCL4) by Western Blot analysis PF4 Polyclonal Antibody (Product # 500-P05-1MG) can be used at a concentration of 0.1-0.2 µg/mL. When used in conjunction with compatible secondary reagents the detection limit for Recombinant Human PF-4 (CXCL4) is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot: To detect Human PF-4 (CXCL4) by Western Blot analysis PF4 Polyclonal Antibody (Product # 500-P05-1MG) can be used at a concentration of 0.1-0.2 µg/mL. When used in conjunction with compatible secondary reagents the detection limit for Recombinant Human PF-4 (CXCL4) is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Sandwich ELISA: To detect Human PF-4 (CXCL4) by sandwich ELISA (using 100 µL/well) a concentration of 0.5-2.0 µg/mL of PF4 Polyclonal Antibody (Product # 500-P05-1MG) is required. This antigen affinity purified antibody, in conjunction with PeproTech PF4 Polyclonal Antibody, Biotin (Product # 500-P05BT-1MG) as a detection antibody, allows the detection of at least 2000-4000 pg/mL of Recombinant Human PF-4 (CXCL4).
